Assertio Therapeutics Inc.

The momentum for this stock is not very good. Assertio Therapeutics Inc. is not a good growth stock. Assertio Therapeutics Inc. is not very popular among insiders. Assertio Therapeutics Inc. is a mediocre stock to choose.

Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products t...

News

Assertio Holdings: Management Change Could Improve Comeback Chances

Seeking Alpha - Long Ideas Assertio Holdings: Management Change Could Improve Comeback Chances...\n more…

Assertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024

Globe Newswire LAKE FOREST, Ill., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ( Assertio or the Company ) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...\n more…

Assertio Holdings, Inc. (NASDAQ:ASRT) Not Doing Enough For Some Investors As Its Shares Slump 30%

Simply Wall St Assertio Holdings, Inc. ( NASDAQ:ASRT ) shares have retraced a considerable 30% in the last month, reversing a fair...\n more…

Assertio Holdings management to meet virtually with Lake Street

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Assertio Holdings management to meet virtually with Lake Street

Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research Assertio (ASRT) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.13 per share a year ago. These figures are...\n more…